MYGN (Myriad Genetics) Valuation Rank

View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Myriad Genetics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Myriad Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (NAS:MYGN) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

0K3W:UK MYD:Germany MYD:Germany MYD:Germany

Address

320 Wakara Way, Salt Lake City, UT, USA, 84108

Website

https://www.myriad.com

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Executives

Paul J Diaz	director, officer: President and CEO	680 SOUTH FOURTH STREET, LOUISVILLE KY 40202
Dale Muzzey	officer: Chief Scientific Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Heinrich Dreismann	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Reitan Colleen F	director	300 THIRD STREET, CAMBRIDGE MA 02142
Margaret Ancona	officer: SVP, Chief of Staff	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Rashmi Kumar	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Lee Nisley Newcomer	director	264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
Richard Bryan Riggsbee	officer: Chief Financial Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Nicole Lambert	officer: Chief Operating Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Pamela Wong	officer: Chief Legal Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Shereen Solaiman	officer: Chief People Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Bisaro	director
Kevin Richard Haas	officer: Chief Technology Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Natalie Munk	officer: Chief Accounting Officer	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116